China Healthcare Summit - Award Winners
For several years, BayHelix has hosted the China Healthcare Awards, celebrating outstanding individuals and companies for their achievement and contribution to the local healthcare ecosystem. In 2021, BayHelix and BioCentury will jointly host the 8th China Healthcare Summit (Nov. 16-19, Grand Hyatt Shanghai + Digital), and will present the awards in six categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; Person of the Year; and Woman Leader of the Year. Congratulations to the 2021 BayHelix Award Winners listed below.
CONGRATULATIONS TO ALL THE 2021 AWARD WINNERS
R&D Achievement of the Year | Brii Biosciences
R&D Achievement of the Year, recognizing a scientific discovery in China with direct impact to drug and/or MedTech R&D or a significant achievement in pharmaceutical and/or MedTech development milestones.
SARS-CoV-2 monoclonal antibody combination (BRII-196/BRII-198). It is currently under review for Emergency Use Authorization (EUA) with the U.S. FDA.
Deal of the Year | RemeGen / Seagen
Deal of the Year, recognizing a groundbreaking pharmaceutical and/or MedTech fund-raising, collaboration, technology transfer, licensing, M&A or joint venture that involves a Chinese entity, either within China or cross-border.
RemeGen Co. Ltd. and Seagen Inc.
Global collaboration for development and commercialization of disitamab vedotin , a novel HER 2 targeted antibody drug conjugate that combines Seagen's drug linker technology with RemeGen’s novel HER2 antibody. RemeGen received $200M
Commercial Achievement of the Year | CanSino Biologics Inc.
Commercial Achievement of the Year, recognizing a creative model that delivered superior value to patients/payers in China and commercial success.
CanSino Biologics Inc.
CanSino developed Convidecia , a single shot adenovirus serotype 5 (Ad5 nCoV) vector vaccine for protection against COVID 19, and obtained approval in 2021 in China and several other countries.
Company of the Year | I-Mab Biopharma
Company of the Year, recognizing an outstanding company in China that has made a significant impact on the landscape, reputation and ecosystem of China’s pharmaceutical, MedTech and/or healthcare industry.
Established in 2016, I-Mab has built a pipeline of 20 clinical and preclinical assets pursuing both a global and China development strategy. In September 2020, I-Mab granted AbbVie global rights(Ex-China) to lemzoparlimab , an anti CD47, for $180M upfront (plus a $20M milestone) and up to $1.74B total in milestones.
Person of the Year | Bo Ying, Founder & CEO, Suzhou Abogen Biosciences Co. Ltd.
Person of the Year, recognizing an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem for drug and/or MedTech R&D, deal transactions, and/or commercialization etc. in China.
Dr. Bo Ying
As founder and CEO of mRNA vaccine developer Suzhou Abogen Biosciences Co. Ltd., Bo has led the company to a rapid rise in 2021, including a massive $720M series C in August and approval by China regulators in June to start a Phase III trial of Abogen’s COVID 19 vaccine ARCoV.
Woman Leader of the Year | Jasmine Cui, Ph.D., Co-founder, Chairwoman & CEO, InnoCare Pharma Ltd.
Woman Leader of the Year, recognizing an outstanding female leader whose contributions have changed the landscape, reputation and ecosystem for biopharma or MedTech in China.
Dr. Jasmine Cui
As Co-founder, Chairwoman & CEO, Jasmine has led rapid growth of InnoCare Pharma since its 2015 launch. After a 2020 IPO in HK, 2021 brought a watershed deal with Biogen, which paid $125M upfront, plus $812M in milestones, to license InnoCare’s orelabrutinib , a CNS penetrant Btk inhibitor for MS and autoimmune diseases.
For a list of last year’s winners, please visit the 2020 China Summit web page here.
For a list of 2019's winners, please visit the 2019 China Summit web page here.